ABAlexandra G. Bell

Alexandra G. Bell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra G. Bell has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A versatile fluorescent reporter for Usutu virus drug screening and infection tracking

    by Amy N Nelson, Aaron E Lin, Saloni Sinha, Sydney J Mullin, Jianche Liu, Alexandra G Bell, Sebastian S Carver, Jason Sethiadi, Jiayu Zhang, Brigitte L Heller, et al.

    Usutu virus (USUV) is an emerging mosquito-borne orthoflavivirus closely related to West Nile and Japanese encephalitis viruses. Despite its increasing prevalence in Europe and reports of neuroinvasive disease in humans, the molecular and immunological determinants of USUV infection remain poorly understood, largely due to the absence of tractable experimental tools. Here, we report the generation and characterization of the first full-length fluorescent reporter USUV. Using a previously established infectious clone of the Vienna 2001 strain, we inserted the mScarlet-I gene into a permissive region of the viral genome, generating a stable and replication-competent reporter virus. In human hepatoma cells, USUV-mScarlet exhibited replication kinetics comparable to wild-type virus and maintained fluorescence over at least 10 serial passages. Application of this system identified remdesivir and interferon-alpha 2a (IFN-α2a) as potent USUV inhibitors and revealed robust induction of the type I IFN response in infected mouse fibroblasts, despite overall attenuation in this cell type. In IFN signaling deficient mice, which are permissive for viral replication, USUV-mScarlet infection resulted in transient disease and reporter expression in multiple peripheral tissues. Among splenocytes, specific myeloid cell subsets were highly enriched in reporter expression, suggesting their role as targets of viral infection. Collectively, these findings demonstrate that USUV-mScarlet recapitulates wild-type infection dynamics in human hepatoma cells while enabling single-cell/quantitative visualization and sorting of infected cells to assess viral spread and host responses. This reporter platform provides a versatile tool for studying USUV biology and will facilitate the development of targeted antivirals and vaccines against this emerging orthoflavivirus.

  • Open Access

    Multimodal control of Cas13d activity through domain insertion at an allosteric hotspot

    by Liyuan Zhu, Long T. Nguyen, Alexandra G. Bell, Tom Krebel, Kara M. Gillmann, Qinhao Cao, Harrison Oatman, Jack Hariri, Andreas Möglich, Cameron Myhrvold, et al.

    CRISPR-Cas13d RNA nucleases are powerful tools for programmable RNA targeting. A light-controlled RNA nuclease could be transformative by enabling researchers to selectively knock down transcripts at desired positions in a cell or tissue or at timepoints of interest. Here, we develop a set of RfxCas13d tools that can be multimodally controlled by either light or small molecule addition. By screening an RfxCas13d library containing insertions of the AsLOV2 photoswitchable domain, we identify an OptoCas13d-off variant that induced target RNA cleavage in the dark and switched to an inactive state under blue light. We show that the same allosteric hotspot can be exploited to generate an OptoCas13d-on with an inverted light response and a ChemoCas13d that is activated by rapamycin analogs, enabling knockdown of endogenous mRNA and protein targets. Overall, our study shows that engineered allostery can produce stimulus-controlled Cas13d variants to modulate RNA with high spatial and temporal precision.


  • Open Access

    Towards deployable CRISPR-based nucleic acid detection

    by Andrew Guo, Alexandra G Bell, Cameron Myhrvold

    Deployable diagnostics are necessary for the control and treatment of infectious diseases, with significant unmet needs revealed during the COVID-19 pandemic. Nucleic acid diagnostics remain among the most sensitive and specific forms of detection, yet their reliance on laboratory equipment and trained personnel limits their deployment in resource limited settings. CRISPR-based diagnostics are uniquely positioned to enable rapid, affordable, and highly accurate nucleic acid testing at both the point-of-care and the point-of-need. In this review, we discuss advances toward deployable CRISPR-based diagnostics. We begin by examining innovations in sample processing methods, emphasizing strategies that reduce equipment requirements and enhance compatibility across diverse sample types and pathogens. We then explore developments in one-pot isothermal and amplification-free approaches, comparing the benefits and tradeoffs associated with each, as well as multiplexing strategies for simultaneous detection of multiple pathogens. Finally, we consider additional factors that impact assay deployability, including reagent lyophilization to minimize cold chain dependence and readout technologies that enable detection in resource-limited settings. We conclude by outlining remaining challenges and opportunities for future progress.


  • Top Cited Papers
    Open Access

    A streamlined CRISPR-based test for tuberculosis detection directly from sputum

    by Alexandra G. Bell, Owen R. S. Dunkley, Nisha H. Modi, Yujia Huang, Soleil Tseng, Robert Reiss, Naranjargal Daivaa, J. Lucian Davis, Deninson Alejandro Vargas, Padmapriya Banada, et al.

    Mycobacterium tuberculosis ( Mtb ) is a major threat to global health, and there is an urgent need for affordable, simple tuberculosis (TB) diagnosis in underresourced areas. Here, we combine recombinase polymerase amplification with Cas13a and Cas12a detection to create two parallelized one-pot assays that detect two conserved elements of Mtb ( IS6110 and IS1081 ) and a human DNA internal control. These assays are compatible with lateral flow and can be readily lyophilized. Our final assay showed a limit of detection of 69.0 CFU per milliliter for Mtb H37Rv and 80.5 CFU per milliliter for Mycobacterium bovis BCG in spiked sputum, with no cross-reactivity to diverse bacterial or fungal isolates. Clinical tests on 13 blinded sputum samples revealed 100% (six of six) sensitivity and 100% (seven of seven) specificity compared to culture. SHINE-TB streamlines TB diagnosis from sample to answer by combining amplification and detection while being compatible with lateral flow and lyophilization.